Outcome of the Rights Issue

The subscription period in the Rights Issue ended on November 28, 2022. In total, 4,118,487shares, divided into 363,640class A shares and 3,754,847class B shares, were subscribed for with and without support of subscription rights, corresponding to approximately 26.7 percent of the Rights Issue. 3,938,716 shares were subscribed for with subscription rights, corresponding to approximately 25.5 percent, whereas 179,771shares were subscribed for without subscription rights, corresponding to approximately 1.2percent of the Rights Issue.

Through the Rights Issue, the Company receives approximately SEK 4.5 million before deduction of issue costs, which amount to approximately SEK 0.8 million.

Notice of allotment and delivery

Allotment of units subscribed for without subscription rights, has been carried out in accordance with the allotment principles set out in the memorandum that was published on November 11, 2022. Notification of the allotment of units subscribed for without unit rights, will be sent via a separate settlement note. Nominee shareholders receive notification of allotment in accordance with the respective nominee's routines. 

Trading in so-called paid subscribed shares (BTA) takes place on Nasdaq First North Growth Market until the conversion of BTA into shares, which takes place after the Rights Issue have been registered at the Swedish Companies Registration Office. Registration at the Swedish Companies Registration Office is expected to take place during week 50, 2022.

Changes in share capital and number of shares

Through the Rights Issue, the number of shares in Cline increases by 4,118,487 shares, of which 363,640class A shares and 3,754,847class B shares, from 15,452,737 shares to 19,571,224shares, and the share capital increases by SEK 411,848.70, from SEK 1,545,273.70 to SEK 1,957,122.40, corresponding to a dilution effect of approximately 21.0 percent.

For more information, please contact:

Patrik Sundh, CEO

Email: patrik.sundh@clinescientific.com

Phone: +46 703-585 088

About Cline Scientific

Cline Scientific develops advanced cancer diagnostics and regenerative medicine treatments. Cline's unique patented surface nanotechnology provides solutions to critical challenges for cell-based products and process in Life Science. Cline is driving two projects through to a clinical stage, StemCART - a stem cell therapy for joint repair, and CellRACE- a cancer diagnostic to predict metastasis.

The company is listed on the Nasdaq First North Growth Market. Redeye AB is Cline Scientific's Certified Adviser.

This information is information that Cline Scientific is required to disclose pursuant to the EU Market Abuse Regulation. The information was submitted for publication by the contact person set out above, at 17:45 CET on 30 November 2022.

Important Information
The publication, release or distribution of this press release may be subject to restrictions in certain jurisdictions. Recipients of this press release in those jurisdictions where this press release has been published, disclosed or distributed should inform themselves of and observe any such restrictions. This press release does not constitute an offer of, or an invitation to acquire or subscribe for, any securities of Cline Scientific in any jurisdiction.

This press release does not constitute an offer or invitation to purchase or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended. The information contained in this press release may not be released, published, copied, reproduced or distributed, directly or indirectly, in whole or in part, in or into the United Kingdom, the United States, Canada, Japan, Australia, Hong Kong, New Zealand, South Africa, South Korea or any other jurisdiction where such release, publication or distribution would be contrary to applicable law or regulation.

Within the European Economic Area, no securities are offered to the public in any country other than Sweden.

This press release contains certain forward-looking information that reflects the Company's current views on future events and financial and operational developments. Words such as "intends", "estimates", "expects", "may", "plans", "believes", "estimates" and other expressions which imply indications or predictions of future developments or trends, and which are not based on historical facts, constitute forward-looking information. Forward-looking information is inherently subject to known and unknown risks and uncertainties because it depends on future events and circumstances. Forward-looking information is not a guarantee of future performance or development, and actual results may differ materially from those expressed in the forward-looking information.

Cline Scientific AB (publ)Phone: 031-387 55 55

Argongatan 2CEmail: info@clinescientific.com

431 53 MÖLNDAL Website: www.clinescientific.com